To reassess earlier suggested type I diabetes (T1D) associations of the insulin receptor substrate 1 (IRS1) and the paired domain 4 gene (PAX4) genes, the Type I Diabetes Genetics Consortium (T1DGC) evaluated single-nucleotide polymorphisms (SNPs) covering the two genomic regions. Sixteen SNPs were evaluated for IRS1 and 10 for PAX4. Both genes are biological candidate genes for T1D. Genotyping was performed in 2300 T1D families on both Illumina and Sequenom genotyping platforms. Data quality and concordance between the platforms were assessed for each SNP. Transmission disequilibrium testing neither show T1D association of SNPs in the two genes, nor did haplotype analysis. In conclusion, the earlier suggested associations of IRS1 and PAX4 to T1D were not supported, suggesting that they may have been false positive results. This highlights the importance of thorough quality control, selection of tagging SNPs, more than one genotyping platform in high throughput studies, and sufficient power to draw solid conclusions in genetic studies of human complex diseases.
Introduction
To reassess earlier suggested type I diabetes (T1D) associations of the insulin receptor substrate 1 (IRS1) and the paired domain 4 gene (PAX4) genes, the Type I Diabetes Genetics Consortium (T1DGC, http://www. t1dgc.org) evaluated single-nucleotide polymorphisms (SNPs) covering the two genomic regions. The design and sample size of the study, genotyping 2295 affected sibpair (ASP) families from nine cohorts, should have adequate power to draw conclusions about the possible T1D association of these two candidate genes.
The IRS1 gene on chromosome 2q36 is the substrate of the insulin receptor tyrosine kinase participating in insulin signaling. The protein is expressed in a variety of insulin responsive cells and tissues. Binding of insulin to its receptor induces phosphorylation of the cytosolic substrates IRS1 and IRS2. Activation of IRS1 is a key initial step in the insulin-signaling pathway. Functional studies of variants in the IRS1 gene showed impaired insulin signaling through the PI3-kinase pathway 1 and impaired insulin secretion.
2 IRS1 can be considered as a biological candidate gene in type II diabetes (T2D) as well as T1D.
A SNP in the IRS1 gene (rs1801278, G972R) was initially shown associated with T2D in several studies. [3] [4] [5] Although later studies questioned this association, [6] [7] [8] a recent genome-wide association study found convincing association to T2D for SNPs adjacent to the IRS1 gene. 9 In addition, a possible IRS1 gene association to T1D has not been clearly resolved. Two independent studies suggested association of the T2D-associated SNP (rs1801278) with T1D. The first study was an Italian case-control and family study 10 and the second studied 4700 US/UK families. 11 Replication of these findings was not achieved either in a large study of 42000 families, 12 or in a Danish meta-analysis combining T1D studies of IRS1. 13 In addition, there have been no evidence from recent genome-wide association scans supporting association of T1D with a region near IRS1. 7, 14, 15 The PAX4 gene on chromosome 7q32 belongs to a family of transcription factors containing a paired box domain involved in organogenesis of the embryo. The transcription factors PAX4 and PAX6 are presumed to trigger early events in cell differentiation, including mediating the differentiation of the endoderm-derived endocrine pancreas. 16 In mice, PAX4 is essential for the differentiation of insulin-producing b cells in pancreas. 17 Recent studies also suggested this gene to be crucial for mature b-cell expansion and survival. 18 As with the case of IRS1, SNPs in PAX4 have been associated with T2D in both Japanese and African-American populations. [19] [20] [21] [22] [23] A PAX4 missense SNP (rs712701) has been reported to be associated with T1D; 24 however, subsequent studies were not able to replicate this finding in Finnish, Hungarian, UK, US, or Danish populations. [25] [26] [27] [28] Further, there was no evidence for an association of T1D with the region on chromosome 7q32 containing PAX4 in recent genome-wide association scans of T1D. 7, 14, 15 It remains possible that significant genetic heterogeneity or population differences may exist and help explain the lack of replication related to both IRS1 and PAX4 with T1D. 29 In this report, we present data from well-powered studies in ASP families with T1D. A panel of tagging SNPs for IRS1 and PAX4 has been genotyped to assess the association of both of these biological candidate genes with respect to their function in T1D susceptibility.
Results
SNPs were genotyped in a set of 11 159 individuals comprising 5003 T1D affected individuals collected by the T1DGC. In total, the material comprised 2298 T1D nuclear families of which 2107 families were of European origin and 191 were Asian-Pacific. A total of 1942 individuals (of the 11 159) were removed from the analyses because of missing phenotype information.
Genotyping of IRS1 and PAX4 SNPs was performed on both the Illumina and the Sequenom platforms (Table 1) . Individuals and SNPs that had call rates below 90% were removed from analysis; genotyping success rate in remaining individuals was then determined. For IRS1 evaluation, a total of 7961 individuals were successfully genotyped on the Illumina platform (genotyping success rate for 16 SNPs was 99.88%) and had phenotype information making them eligible for analysis. For the Sequenom platform, a total of 7896 individuals had a genotyping success rate of 99.33% and were included in the final analyses. For PAX4, a total of 8005 individuals were successfully genotyped on the Illumina platform (genotyping success rate for 10 SNPs of 99.42%) and a total of 7878 individuals on the Sequenom platform (genotyping success rate 98.95%) were included for analyses.
In the aggregate data of ASP families, all SNPs had genotypic distributions that were consistent with HardyWeinberg Equilibrium expectations (P40.001, data not shown). Linkage disequilibrium within the IRS1 and PAX4 genes ( Figure 1a No association of the IRS1 and PAX4 genes with T1D R Bergholdt et al S50 significant evidence observed that supported an association for SNPs in any of the two genes with T1D (Table 2) . For IRS1 SNPs, no consistent association to T1D was shown (Table 2 ). Two IRS1 SNPs were significantly associated with T1D (Po0.05) in the Illumina data; however, one SNP was not genotyped on Sequenom and the other SNP did not attain statistical significance (P ¼ 0.09). It should be noted that the second SNP had equal 'missingness' values and high concordance rate with the Illumina data. One SNP in IRS1 was significantly associated (P ¼ 0.04) in Sequenom data, but not (P ¼ 0.43) in the Illumina data. This inconsistency may be due to a higher rate of 'missingness' because of difficulty in genotyping calls on the Sequenom platform.
In PAX4, the missense SNP, rs712701, exhibited substantial heterogeneity in the Illumina data (P ¼ 0.02), whereas random transmission was observed in the Sequenom data ( Table 2 ). The concordance rate for all genotyped individuals for this SNP was lower than other SNPs, suggesting technical problems regarding genotyping of this SNP. All other SNPs in the PAX4 region did not exhibit a significant association with T1D. On the basis of these data, PAX4 is not associated with T1D, although this study shows that genotyping results of rs712701 should be interpreted with caution.
Discussion
We have evaluated the association of IRS1 and PAX4 SNPs with T1D in a large collection of ASP families. We report on aggregate data only in this study, but minor population differences exist. In IRS1, the SNP rs6725330 showed significant association to T1D in the HBDI collection (428 families; 921 individuals), particularly in the Illumina genotyping data (P ¼ 0.0005); however, this SNP did not reach statistical significance in other populations.
Analyses using both TDT and pedigree disequilibrium test methods were performed for two-and three-marker haplotypes for markers in both genes (excluding SNP rs712701 in PAX4). Calculations were performed using the TDTPHASE and PDTPHASE options in UNPHASED v2.404. 30 There was no evidence of association with any two-or three-marker haplotype, consistent with the lack of significant evidence of association with SNP analyses.
In summary, the earlier suggested associations of IRS1 and PAX4 to T1D are not supported in this study. These data suggest that the original findings may have been false positive results because of insufficient sample size to detect effects of the magnitude reported. This study highlights the importance of thorough quality control, carefully chosen tagging SNPs, more than one genotyping platform in high throughput studies, and robustly designed experiments to provide enough power to draw solid conclusions in genetic studies of human complex diseases.
Materials and methods

Samples
The T1DGC has assembled a collection of ASPs families for the detection of T1D susceptibility genes (http:// www.t1dgc.org). Samples used in this project consisted of 2295 ASP families from nine cohorts. The families in this study were collected from the following T1DGC networks and contributing sites: 9% Asia-Pacific, 29% rs16822551  rs11683087  rs2251692  rs17208239  rs17208470  rs2435185  rs4675095  rs1801278  rs1801123  rs6725330  rs6725556  rs13018009  rs4675096  rs956115  rs957797  rs3779536  rs806213  rs3735640  rs806216  rs3824006  rs10229583  rs712701  rs327518  rs7801118  rs806187 European, 35% North American, and 27% UK/Sardinian. The majority of the subjects were Caucasian (81%) with 18% unknown ethnicity and 1% other (Asian, African American, Pacific Islander).
Genotyping
SNPs in IRS1 and PAX4 were genotyped on two platforms (Illumina and Sequenom). Details of the sample, quality control, and other aspects of the data can be found in this volume (Brown et al. 31 ) Individuals and SNPs that had call rates below 90% were removed from analysis. For IRS1 on the Illumina platform, genotyping success rate for 16 SNPs was 99.88%; on the Sequenom platform, the genotyping success rate was 99.33%. For PAX4 on the Illumina platform, the genotyping success rate for 10 SNPs was 99.42%; on the Sequenom platform, the genotyping success rate was 98.95%. All 16 SNPs covering the IRS1 gene were successfully genotyped on the Illumina platform, whereas only 14 of these could be genotyped on the Sequenom platform (rs2251692 and rs956115 failed on Sequenom). All SNPs had minor allele frequencies 41%, and concordance rates between the two genotyping platforms were above 99.9% for most SNPs (Table 1) .
Statistical analysis
Data quality checks, using standard methods including the PedCheck program, are reported by Brown et al. (this volume) . The linkage disequilibrium plots and TDT analyses for the haplotypes were computed using Haploview software (http://www.broad.mit.edu/mpg/ haploview). TDT analyses were performed by using PLINK software. 32 Analyses using both TDT and pedigree disequilibrium test methods were performed for two-and three-marker haplotypes for markers in both genes (excluding SNP rs712701 in PAX4). Calculations were done using the TDTPHASE and PDTPHASE options in UNPHASED v2.404. 30 
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